DIVERSIFYING FOR SUCCESS
Leaders at Exyte discuss their drive to expand and support the Life Science sector in Ireland, bringing surety to facility delivery through efficiencies and innovation
Exyte is a global leader in the design, engineering and delivery of high-tech facilities to key industries. With offices in Dublin and now Cork, Exyte continues to build on its strong performance, with a turnover of approximately €7 billion for 2022. Exyte has an accelerated growth strategy, ‘Pathway to Ten’, with the objective to reach annual sales of €10 billion by 2027. Currently executing major projects in Ireland, Exyte is driving regional growth and its new office in Cork was established to further facilitate the expansion of the Biopharma and Life Sciences (BLS) business segment.
Exyte’s Biopharma and Life Sciences business places sharp focus on client requisites in delivering facilities and manufacturing plants which are working tirelessly to bring crucial drugs to market and secure international supply lines. Ronan Donohue holds a key global role in Exyte and drives Exyte’s biopharma’s global perspective, with responsibility for global project delivery including engineering and construction.
“The Life Science sector is a key component of our target ‘Pathway to Ten’ goal and reflects both the ambitions, talent and capabilities at Exyte. The rapid changes in the Pharma and BioPharma industry have brought challenges and opportunities. In response, Exyte has achieved significant growth in the sector because of our innovative and flexible approach to project execution incorporating modular and off-site solutions while maintaining a focus on predictability of delivery, which is key for our clients. Exyte is a safe pair of hands,” said Ronan.
Construction sector dynamics have focused on supply chain, resourcing and the adoption of new technologies. Exyte strategically invested and integrating new technologies to continually increase the expertise and capability to design and build facilities of the future.
ExyCell®, a high-quality modular system tailored to meet client needs to reduce time-to-market, ensures cost certainty and enhance safety and quality to biomanufacturing production facilities. ExyCell® has been devised to minimise time to market for new vaccines and has proven highly successful on several projects in delivering the rapid, modular construction of biopharma production facilities developed by Exyte who are currently exploring opportunities in Ireland.
Exyte offers full EPCMQ services to highly complex projects on behalf of the world’s leading Life Science multinationals and is trusted by clients to provide services from architectural design, technical building infrastructure and engineering through to automation, commissioning and qualification. Exyte takes on overall responsibility for quality assurance and delivering the project within the set timeframe and budget.
A key component is managing the complexities of the supply-chain. Exyte has identified and developed a trusted value chain in Ireland based on previous project experience. Its collaborative approach helps ensure quality with on-time/on-budget delivery at each milestone and a smooth delivery process. Reliability of supply-chain to offer innovative solutions in supporting Exyte’s procurement teams in sourcing authorised marketplaces for sustainable materials is critical.
Padraic Brennan explained that: “Ireland is the world’s third largest net exporter of pharmaceuticals and a global powerhouse in the Life Science sector, with significant investment expected in major projects from biotechnology to filling, API and cell & gene therapy. Exyte actively listens and aligns to provide solutions and work with stakeholders to get each project over the line.”
Padraic has extensive expertise in the delivery of global projects in the Life Science and Food & Beverage sectors. He went on to say that Ireland is a hub for the world’s largest global pharmaceutical and biopharma because of a highly educated young and versatile workforce and proximity to markets. An industry leader, Exyte looks to continue sustainable growth in Ireland, based on a strong performance with a reputation for industry knowledge and project delivery management. The new office in Cork is providing additional resources to Life Science projects, which is one of the most regulated industries, with complex challenges and requires future focused design and engineering partners to implement time critical projects and innovation to drive their success.
“The global market for pharmaceutical applications is changing, driven by technical innovations such as mRNA and by the further spread of civilization diseases. In consequence the demand for drugs, medicines and other medical treatments increases. Exyte sees great potential in this market. The expansion of this business is a key field of action for us.”
Exyte brings together project stakeholders to align client vision, infusing specialist know-how with innovation and efficiency. Surety of delivery is a key objective and Exyte is excited to work with clients in Ireland to ensure satisfaction, managed through high quality finish, with excellence in Health and Safety.
“Exyte carries the ball through all facets of the project. Delivering projects using EPC is unique to Exyte and will take on the full responsibility for cradle to grave delivery. The convergence of tech and health is becoming reality, while the promise of cell and gene therapy is finally being delivered to patients. We see over €15 billion investment within Ireland and Northern Europe over the next five years in pharmaceutical projects including Biotech, Fill Finish, API, Gene & Cell Therapy as well as blood fractionation and vaccines and we have the unique skillsets that has developed over the last two years with multinational pharmaceutical clients that have invested in Ireland,” said Padraig Finn, Vice President Business Acquisition & Growth.
Exyte’s technical division is led by Steven Griffin, Director of Projects, Biopharma and Life Science Northern Europe. Along with over 20 years’ experience executing life science projects in Ireland, Steven is a Certified Senior Project Manager and Chartered Engineer.
”Exyte has all the fundamental for success in Ireland. Our multi-disciplinary teams coordinate with Exyte’s team Global Subject Matter Experts to input global expertise to projects when required. Strong process know-how combined with our understanding of regulatory and GMP requirements along with digital transformation solutions offers value and insights at every stage of a project.”
Exyte has a culture of Diversity & Inclusion with a One-Team approach and boasts ambitious teams who bring expertise and energy to each client and every project. Exyte values employees as the key element in driving success and the ‘Pathway to Ten’. Respectful engagement within its multicultural environment is part of the Exyte ethos and philosophy. Mixing expertise within teams is key to knowledge transfer, innovation and building a leadership pipeline within a diverse pool of talent in Ireland. Exyte employs based on ability, experience and enthusiasm, irrespective of demographic and that’s why Exyte recruits and retains great talent.
Commenting on careers at Exyte, Liz Allen, Director of Engineering, Biopharma and Life Sciences Northern Europe said: “Our recent project success means we are continuing to expand roles and welcome new talent to inject their ideas and enthusiasm. If you wish to be in a dynamic environment, on international projects and with a strong career compass, then Exyte is a great choice.”
To attract new talent Exyte recently launched its new employer brand #ExyteCareersAreExciting
Visit https://careers.exyte.net or scan the QR code, to explore the wide variety of positions.
_____________________________________________________
Denise Maguire Editor of Irish Construction Industry Magazine & Plan Magazine
Email: denise@mcdmedia.ie WWW.MCDMEDIA.IE WWW.IRISHCONSTRUCTION.COM